Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-100 Safety Study in Severe COVID-19 and Pneumonia
NCT04659122Phase 1Terminated
- Sponsor
- Airway Therapeutics
- Start
- Aug 2021
- Primary completion
- Feb 2023
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of zelpultide alfa in coronavirus disease 2019 (COVID-19) and community acquired pneumonia (CAP) (3 arms), sponsored by Airway Therapeutics. Primary endpoint: Highest-tolerated & safety-tested AT-100 dose up to 7 days. Started Aug 2021; status: terminated.
02
Drugs
zelpultide alfa
03
Conditions
coronavirus disease 2019 (COVID-19)community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT04659122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04659122.